These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 19880858)
21. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Sakata Y; Ohtsu A; Horikoshi N; Sugimachi K; Mitachi Y; Taguchi T Eur J Cancer; 1998 Oct; 34(11):1715-20. PubMed ID: 9893658 [TBL] [Abstract][Full Text] [Related]
22. S-1 in gastric cancer: a comprehensive review. Maehara Y Gastric Cancer; 2003; 6 Suppl 1():2-8. PubMed ID: 12775012 [TBL] [Abstract][Full Text] [Related]
23. Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent (drug combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) to rats. Yoshisue K; Masuda H; Matsushima E; Ikeda K; Nagayama S; Kawaguchi Y Drug Metab Dispos; 2000 Oct; 28(10):1162-7. PubMed ID: 10997934 [TBL] [Abstract][Full Text] [Related]
24. [Concentration of FT and CDHP and 5-FU in the ascites fluid of patient with peritoneal carcinomatosis after new anti-cancer drug TS-1 oral administration]. Iizuka R; Takahashi S; Kakihara N; Matsumura H; Takenaka A Gan To Kagaku Ryoho; 2002 Jul; 29(7):1251-3. PubMed ID: 12146009 [No Abstract] [Full Text] [Related]
25. Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer. Hirose T; Fujita K; Nishimura K; Ishida H; Yamashita K; Sunakawa Y; Mizuno K; Miwa K; Nagashima F; Tanigawara Y; Adachi M; Sasaki Y Oncol Rep; 2010 Aug; 24(2):529-36. PubMed ID: 20596643 [TBL] [Abstract][Full Text] [Related]
26. Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer. Lee SJ; Cho SH; Yoon JY; Hwang JE; Bae WK; Shim HJ; Chung IJ Cancer Chemother Pharmacol; 2009 Dec; 65(1):159-66. PubMed ID: 19479256 [TBL] [Abstract][Full Text] [Related]
27. Effect of food and a proton pump inhibitor on the pharmacokinetics of S-1 following oral administration of S-1 in patients with advanced solid tumors. Scheulen ME; Saito K; Hilger RA; Mende B; Zergebel C; Strumberg D Cancer Chemother Pharmacol; 2012 Mar; 69(3):753-61. PubMed ID: 22020317 [TBL] [Abstract][Full Text] [Related]
28. Effect of gastrectomy on the pharmacokinetics of 5-fluorouracil and gimeracil after oral administration of S-1. Tsuruoka Y; Kamano T; Kitajima M; Kawai K; Watabe S; Ochiai T; Sakamoto K; Shirasaka T Anticancer Drugs; 2006 Apr; 17(4):393-9. PubMed ID: 16549996 [TBL] [Abstract][Full Text] [Related]
29. A phase I study of bi-weekly combination therapy with S-1 and docetaxel for advanced or recurrent gastric cancer. Rino Y; Takanashi Y; Yukawa N; Saeki H; Wada H; Kanari M; Yamada R; Satoh T; Yamamoto N; Imada T Anticancer Res; 2006; 26(2B):1455-62. PubMed ID: 16619558 [TBL] [Abstract][Full Text] [Related]
30. Alternative pharmacokinetics of S-1 components, 5-fluorouracil, dihydrofluorouracil and alpha-fluoro-beta-alanine after oral administration of S-1 following total gastrectomy. Kim WY; Nakata B; Hirakawa K Cancer Sci; 2007 Oct; 98(10):1604-8. PubMed ID: 17683513 [TBL] [Abstract][Full Text] [Related]
31. [TS-1 treatment for progressive gastric cancer in a patient on chronic dialysis--assessment of dosage regimen by monitoring blood concentrations of therapeutic drugs (TDM)]. Tanaka T; Fujita S; Tanaka N; Ooka M; Okajima S; Tanaka N Gan To Kagaku Ryoho; 2005 Jun; 32(6):841-5. PubMed ID: 15984528 [TBL] [Abstract][Full Text] [Related]
32. Comparison of the pharmacokinetics of S-1, an oral anticancer agent, in Western and Japanese patients. Comets E; Ikeda K; Hoff P; Fumoleau P; Wanders J; Tanigawara Y J Pharmacokinet Pharmacodyn; 2003 Aug; 30(4):257-83. PubMed ID: 14650374 [TBL] [Abstract][Full Text] [Related]
33. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Koizumi W; Kurihara M; Nakano S; Hasegawa K Oncology; 2000 Apr; 58(3):191-7. PubMed ID: 10765119 [TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetic study of S-1 in patients in whom inulin clearance was measured. Ando Y; Kawada K; Inada M; Morita S; Mitsuma A; Yasuda Y; Hiramatsu M; Fujimoto Y; Fujita K Oncology; 2012; 83(1):38-44. PubMed ID: 22722580 [TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of S-1 monotherapy in plasma and in tears for gastric cancer patients. Yasui H; Kawakami T; Kashiwagi H; Mori K; Omae K; Kasai J; Yoshisue K; Kawahira M; Tsushima T; Machida N; Fukutomi A; Yamaguchi K Int J Clin Oncol; 2019 Jun; 24(6):660-665. PubMed ID: 31011915 [TBL] [Abstract][Full Text] [Related]
36. A phase II and pharmacokinetic study of first line S-1 for advanced gastric cancer in Taiwan. Chen JS; Chao Y; Hsieh RK; Cheng AL; Chen PM; Chiou TJ; Chao TY; Yeh KH; Chen LT; Whang-Peng J Cancer Chemother Pharmacol; 2011 Jun; 67(6):1281-9. PubMed ID: 20714726 [TBL] [Abstract][Full Text] [Related]
37. Alternate-day oral therapy with TS-1 for advanced gastric cancer. Arai W; Hosoya Y; Hyodo M; Yokoyama T; Hirashima Y; Yasuda Y; Nagai H; Shirasaka T Int J Clin Oncol; 2004 Jun; 9(3):143-8. PubMed ID: 15221596 [TBL] [Abstract][Full Text] [Related]
38. The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors. Schöffski P Anticancer Drugs; 2004 Feb; 15(2):85-106. PubMed ID: 15075664 [TBL] [Abstract][Full Text] [Related]
39. S-1-induced, prolonged complete regression of lung metastasis from gastric cancer refractory to 5'-DFUR: a case report with pharmacokinetic study. Ueda Y; Yamagishi H; Yamashita T; Itoh N; Itoi H; Shirasaka T; Ajani JA Jpn J Clin Oncol; 2004 May; 34(5):282-6. PubMed ID: 15231865 [TBL] [Abstract][Full Text] [Related]
40. [New oral anticancer drug, TS-1 (S-1)--from bench to clinic]. Shirasaka T; Tsukuda M; Inuyama Y; Taguchi T Gan To Kagaku Ryoho; 2001 Jun; 28(6):855-64. PubMed ID: 11432358 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]